Lessons learned from the development of imatinib

被引：42

作者：

Lydon, NB ^{[1
]}

Druker, BJ ^{[1
]}

机构：

[1] Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97239 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷

关键词：

imatinib; tyrosine kinase; drug design; STI; 571; Bcr-Abl; CML;

D O I：

10.1016/j.leukres.2003.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：S29 / S38

页数：10

共 83 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[3] Mutational analysis of the tyrosine kinome in colorectal cancers [J].

Bardelli, A ;

Parsons, DW ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Saha, S ;

Markowitz, S ;

Willson, JKV ;

Parmigiani, G ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

SCIENCE, 2003, 300 (5621) :949-949

[4]

Beran M, 1998, CLIN CANCER RES, V4, P1661

[5] A chemical switch for inhibitor-sensitive alleles of any protein kinase [J].

Bishop, AC ;

Ubersax, JA ;

Petsch, DT ;

Matheos, DP ;

Gray, NS ;

Blethrow, J ;

Shimizu, E ;

Tsien, JZ ;

Schultz, PG ;

Rose, MD ;

Wood, JL ;

Morgan, DO ;

Shokat, KM .

NATURE, 2000, 407 (6802) :395-401

[6] VIRAL ONCOGENES [J].

BISHOP, JM .

CELL, 1985, 42 (01) :23-38

[7]

Buchdunger E, 1996, CANCER RES, V56, P100

[8]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[9] Bcr-Abl inhibition as a modality of CML therapeutics [J].

Buchdunger, E ;

Matter, A ;

Druker, BJ .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01) :M11-M18

[10] SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS [J].

BUCHDUNGER, E ;

ZIMMERMANN, J ;

METT, H ;

MEYER, T ;

MULLER, M ;

REGENASS, U ;

LYDON, NB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2558-2562

← 1 2 3 4 5 6 7 8 9 →